» Articles » PMID: 16648296

The Ternary IGF Complex Influences Postnatal Bone Acquisition and the Skeletal Response to Intermittent Parathyroid Hormone

Overview
Journal J Endocrinol
Specialty Endocrinology
Date 2006 May 2
PMID 16648296
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

The role of circulating IGF-I in skeletal acquisition and the anabolic response to PTH is not well understood. We generated IGF-I-deficient mice by gene deletions of IGF ternary complex components including: (1) liver-specific deletion of the IGF-I gene (LID), (2) global deletion of the acid-labile (ALS) gene (ALSKO), and (3) both liver IGF-I and ALS inactivated genes (LA). Twelve-week-old male control (CTL), LID, ALSKO, and LA mice were treated with vehicle (VEH) or human PTH(1-34) for 4 weeks. VEH-treated IGF-I-deficient mice (i.e. LID, ALSKO and LA mice) exhibited reduced cortical cross-sectional area (P = 0.001) compared with CTL mice; in contrast, femoral trabecular bone volume fractions (BV/TV) of the IGF-I-deficient mice were consistently greater than CTL (P < 0.01). ALSKO mice exhibited markedly reduced osteoblast number and surface (P < 0.05), as well as mineral apposition rate compared with other IGF-I-deficient and CTL mice. Adherent bone marrow stromal cells, cultured in beta-glycerol phosphate and ascorbic acid, showed no strain differences in secreted IGF-I. In response to PTH, there were both compartment- and strain-specific effects. Cortical bone area was increased by PTH in CTL and ALSKO mice, but not in LID or LA mice. In the trabecular compartment, PTH increased femoral and vertebral BV/TV in LID, but not in ALSKO or LA mice. In conclusion, we demonstrated that the presentation of IGF-I as a circulating complex is essential for skeletal remodeling and the anabolic response to PTH. We postulate that the ternary complex itself, rather than IGF-I alone, influences bone acquisition in a compartment-specific manner (i.e. cortical vs trabecular bone).

Citing Articles

Endocrine and cellular physiology and pathology of the insulin-like growth factor acid-labile subunit.

Baxter R Nat Rev Endocrinol. 2024; 20(7):414-425.

PMID: 38514815 DOI: 10.1038/s41574-024-00970-4.


First use of gene therapy to treat growth hormone resistant dwarfism in a mouse model.

Sia K, Gan S, Mohd Rodhi S, Fu Z, Kopchick J, Waters M Gene Ther. 2022; 29(6):346-356.

PMID: 35105948 PMC: 9203273. DOI: 10.1038/s41434-022-00313-w.


Anabolic actions of PTH in murine models: two decades of insights.

Zweifler L, Koh A, Daignault-Newton S, McCauley L J Bone Miner Res. 2021; 36(10):1979-1998.

PMID: 34101904 PMC: 8596798. DOI: 10.1002/jbmr.4389.


Insulin-like growth factors: actions on the skeleton.

Yakar S, Werner H, Rosen C J Mol Endocrinol. 2018; 61(1):T115-T137.

PMID: 29626053 PMC: 5966339. DOI: 10.1530/JME-17-0298.


IGF-I induced phosphorylation of PTH receptor enhances osteoblast to osteocyte transition.

Qiu T, Crane J, Xie L, Xian L, Xie H, Cao X Bone Res. 2018; 6:5.

PMID: 29507819 PMC: 5827661. DOI: 10.1038/s41413-017-0002-7.